

Gerburg M Wulf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1374087/publications.pdf>

Version: 2024-02-01

76
papers

8,306
citations

81900

39
h-index

88630

70
g-index

81
all docs

81
docs citations

81
times ranked

10405
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1493-1499.	7.0	22
2	Abstract P5-07-01: Proteogenomic analysis of differential chemotherapy responses in patient-derived xenografts of triple-negative breast cancer. <i>Cancer Research</i> , 2022, 82, P5-07-01-P5-07-01.	0.9	0
3	The association of infectious mononucleosis and invasive breast cancer in The Health of Women (HOW) Study. <i>Breast Cancer</i> , 2022, 29, 731-739.	2.9	1
4	A phase I/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1128-TPS1128.	1.6	1
5	Testosterone therapy and breast histopathological features in transgender individuals. <i>Modern Pathology</i> , 2021, 34, 85-94.	5.5	21
6	Blockade of 6-phosphogluconate dehydrogenase generates CD8+ effector T cells with enhanced anti-tumor function. <i>Cell Reports</i> , 2021, 34, 108831.	6.4	23
7	Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic BRCA1/2 (BRCA) or other homologous recombination (HR)-pathway gene mutations (mut) treated with PARP inhibitors (PARPi).. <i>Journal of Clinical Oncology</i> , 2021, 39, 10512-10512.	1.6	1
8	Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells. <i>JCO Precision Oncology</i> , 2021, 5, 896-903.	3.0	6
9	Visualizing the effects of lactate dehydrogenase (LDH) inhibition and LDH genetic ablation in breast and lung cancer with hyperpolarized pyruvate NMR. <i>NMR in Biomedicine</i> , 2021, 34, e4560.	2.8	9
10	Abstract 156: Mutational signature 3 predicts responses to olaparib plus buparlisib in triple-negative breast cancer and high-grade serous ovarian cancer. <i>Cancer Research</i> , 2021, 81, 156-156.	0.9	1
11	Abstract 2992: Proteogenomic characterization of triple-negative breast cancer patient-derived xenografts reveals molecular correlates of differential chemotherapy response and potential therapeutic targets to overcome resistance. , 2021, , .		0
12	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. <i>Nature Communications</i> , 2021, 12, 5563.	12.8	19
13	Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. <i>Cell</i> , 2021, 184, 4753-4771.e27.	28.9	99
14	WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	7
15	Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOc patients treated with buparlisib and olaparib. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 503-514.	2.5	5
16	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.	1.6	276
17	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1598.	7.1	84
18	The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 1226-1239.	9.4	32

#	ARTICLE	IF	CITATIONS
19	Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer. <i>Nature Communications</i> , 2020, 11, 1456.	12.8	91
20	Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition. <i>Cancer Research</i> , 2020, 80, 3033-3045.	0.9	23
21	An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers. <i>BMC Cancer</i> , 2020, 20, 197.	2.6	24
22	Destruction of a Microtubule-Bound MYC Reservoir during Mitosis Contributes to Vincristine's Anticancer Activity. <i>Molecular Cancer Research</i> , 2020, 18, 859-872.	3.4	10
23	Response of Brain Metastases From <i>PIK3CA</i> -Mutant Breast Cancer to Alpelisib. <i>JCO Precision Oncology</i> , 2020, 4, 572-578.	3.0	31
24	Not Black or White but Shades of Gray: Homologous Recombination Deficiency as a Continuous Variable Modulated by RNF168. <i>Cancer Research</i> , 2020, 80, 2720-2721.	0.9	1
25	Efficient Human Cytomegalovirus Replication in Primary Endothelial Cells Is SOCS3 Dependent. <i>Intervirology</i> , 2019, 62, 80-89.	2.8	1
26	Chromosome 12p Amplification in Triple-Negative/ <i>BRCA1</i> -Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. <i>Cancer Research</i> , 2019, 79, 4258-4270.	0.9	17
27	Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1132.	7.1	285
28	How cancers usurp macrophages to keep growing. <i>Cell Research</i> , 2019, 29, 423-424.	12.0	0
29	PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in <i>BRCA</i> -Deficient Models of Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2019, 9, 722-737.	9.4	433
30	Olaparib and \pm -specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , The, 2019, 20, 570-580.	10.7	191
31	Establishing a Cohort of Transgender Men and Gender Nonconforming Individuals to Understand the Molecular Impact of Testosterone on Breast Physiology. <i>Transgender Health</i> , 2019, 4, 326-330.	2.5	13
32	Interdisciplinary Management of Transgender Individuals at Risk for Breast Cancer: Case Reports and Review of the Literature. <i>Clinical Breast Cancer</i> , 2019, 19, e12-e19.	2.4	49
33	Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2018, 8, 354-369.	9.4	62
34	Editorial: EBV-Associated Carcinomas: Presence, Role, and Prevention Strategies. <i>Frontiers in Oncology</i> , 2018, 8, 528.	2.8	6
35	TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1011-1011.	1.6	63
36	Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1255-1262.	2.5	19

#	ARTICLE	IF	CITATIONS
37	Serial-omics of P53 ^{+/+} , Brca1 ^{+/+} Mouse Breast Tumor and Normal Mammary Gland. <i>Scientific Reports</i> , 2017, 7, 14503.	3.3	9
38	Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. <i>Clinical Cancer Research</i> , 2017, 23, 1263-1273.	7.0	95
39	Epstein-Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation. <i>EBioMedicine</i> , 2016, 9, 148-160.	6.1	61
40	Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E4338-47.	7.1	76
41	Deletion of the gene <i>Pip4k2c</i> , a novel phosphatidylinositol kinase, results in hyperactivation of the immune system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 7596-7601.	7.1	48
42	Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton. <i>Cell</i> , 2016, 164, 433-446.	28.9	301
43	The Rab2A GTPase Promotes Breast Cancer Stem Cells and Tumorigenesis via Erk Signaling Activation. <i>Cell Reports</i> , 2015, 11, 111-124.	6.4	80
44	Prolyl Isomerase Pin1 Acts Downstream of miR200c to Promote Cancer Stem-like Cell Traits in Breast Cancer. <i>Cancer Research</i> , 2014, 74, 3603-3616.	0.9	68
45	Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC). <i>Journal of Clinical Oncology</i> , 2014, 32, 2510-2510.	1.6	25
46	PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells. <i>Cell</i> , 2013, 155, 397-409.	28.9	429
47	Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null Tumors. <i>Cell</i> , 2013, 155, 844-857.	28.9	173
48	Rosuvastatin Lowers Circulating Tissue Factor Antigen-Bearing Microparticles In Metastatic Breast Cancer: A Phase II, Multi-Dose, Randomized Trial (MicroSTAT Trial). <i>Blood</i> , 2013, 122, 579-579.	1.4	1
49	Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer. <i>Cancer Discovery</i> , 2012, 2, 1048-1063.	9.4	384
50	Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice. <i>Breast Cancer Research</i> , 2011, 13, R30.	5.0	52
51	Cell-to-Cell Variability in PI3K Protein Level Regulates PI3K-AKT Pathway Activity in Cell Populations. <i>Current Biology</i> , 2011, 21, 173-183.	3.9	91
52	Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 3126-3132.	1.6	207
53	Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 3126-3132.	1.6	10
54	Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review. <i>Breast Cancer: Targets and Therapy</i> , 2010, 2, 37.	1.8	6

#	ARTICLE	IF	CITATIONS
55	Pinning down HER2â€™ER crosstalk in SMRT regulation. Trends in Biochemical Sciences, 2009, 34, 162-165.	7.5	19
56	Essential role of Pin1 in the regulation of TRF1 stability and telomere maintenance. Nature Cell Biology, 2009, 11, 97-105.	10.3	104
57	Altered Proliferation and Differentiation Properties of Primary Mammary Epithelial Cells from BRCA1 Mutation Carriers. Cancer Research, 2009, 69, 1273-1278.	0.9	63
58	The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-Î² production. Nature, 2006, 440, 528-534.	27.8	444
59	Pin1 Regulates Centrosome Duplication, and Its Overexpression Induces Centrosome Amplification, Chromosome Instability, and Oncogenesis. Molecular and Cellular Biology, 2006, 26, 1463-1479.	2.3	108
60	Activation of Î²-Catenin Signaling in Prostate Cancer by Peptidyl-Prolyl Isomerase Pin1-Mediated Abrogation of the Androgen Receptor-Î²-Catenin Interaction. Molecular and Cellular Biology, 2006, 26, 929-939.	2.3	65
61	Phosphorylation-specific prolyl isomerization: is there an underlying theme?. Nature Cell Biology, 2005, 7, 435-441.	10.3	230
62	Pin1 in Acute Myeloid Leukemia Blast Cells.. Blood, 2005, 106, 4539-4539.	1.4	0
63	Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis. EMBO Journal, 2004, 23, 3397-3407.	7.8	173
64	Regulation of NF-Î²B Signaling by Pin1-Dependent Prolyl Isomerization and Ubiquitin-Mediated Proteolysis of p65/RelA. Molecular Cell, 2003, 12, 1413-1426.	9.7	611
65	The prolyl isomerase Pin1 in breast development and cancer. Breast Cancer Research, 2003, 5, 76-82.	5.0	71
66	Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer. Journal of Cell Science, 2003, 116, 773-783.	2.0	173
67	The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Research, 2003, 63, 6244-51.	0.9	179
68	Role of Pin1 in the Regulation of p53 Stability and p21 Transactivation, and Cell Cycle Checkpoints in Response to DNA Damage. Journal of Biological Chemistry, 2002, 277, 47976-47979.	3.4	202
69	PIN1 Is an E2F Target Gene Essential for Neu / Ras -Induced Transformation of Mammary Epithelial Cells. Molecular and Cellular Biology, 2002, 22, 5281-5295.	2.3	250
70	The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature, 2002, 419, 849-853.	27.8	361
71	Pin1 regulates turnover and subcellular localization of Î²-catenin by inhibiting its interaction with APC. Nature Cell Biology, 2001, 3, 793-801.	10.3	447
72	Telomeric protein Pin2/TRF1 induces mitotic entry and apoptosis in cells with short telomeres and is down-regulated in human breast tumors. Oncogene, 2001, 20, 1497-1508.	5.9	54

#	ARTICLE	IF	CITATIONS
73	Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2001, 344, 816-816.	27.0	2
74	The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. <i>Nature</i> , 1999, 399, 784-788.	27.8	687
75	Multidrug resistance phenotype in patients with chronic lymphocytic leukemia as detected by immunofluorescence (FACS) and Northern blot analysis. <i>Leukemia Research</i> , 1994, 18, 475-484.	0.8	18
76	Decrease in soluble CD8 antigen levels in splenectomized patients as an index for reduced suppressor/cytotoxic cell activity. <i>Immunology Letters</i> , 1991, 30, 113-118.	2.5	3